An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia
D. Pal, H. Blair, S. Boyd…·J. Vormoor
This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.